Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11044440 | 0.85 | CA12 (0.50) | CA12CA2CA9KMT2AMEN1 | |
| SCHEMBL13645984 | 0.80 | SIGMAR1 (0.48) | CA12CA2CA9KMT2AMEN1 | |
| SCHEMBL11145951 | 0.80 | CA12 (0.47) | CA12CA2CA9KMT2AMEN1 | |
| SCHEMBL27526879 | 0.79 | NPC1 (0.47) | KMT2AMEN1CYP3A4CYP2C19NPC1 | |
| SCHEMBL4126571 | 0.78 | TAAR1 (0.50) | CA12CA2CA9KMT2AMEN1 | |
| SCHEMBL21676 | 0.78 | CA12 (0.45) | CA12CA2CA9KMT2AMEN1 | |
| SCHEMBL17037834 | 0.78 | SIGMAR1 (0.52) | CA12CA2CA9TAAR1PPARG | |
| SCHEMBL28733423 | 0.77 | APP (0.41) | CA12CA2CA9KMT2AMEN1 | |
| SCHEMBL14851194 | 0.77 | CA12 (0.41) | CA12CA2CA9KMT2AMEN1 | |
| SCHEMBL5048425 | 0.77 | CHRM5 (0.50) | KMT2AMEN1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171345-A1 | 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives | SCHERING AG (DE) | 2003-09-11 | — | — | US | claimed |
| WO-2003033516-A1 | 8β -SUBSTITUTED-11β -ARYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | WO | claimed |
| US-5696268-A | REACTING N-ACYLAMINO ACID DERIVATIVE WITH OPTICALLY ACTIVE ENAMINE DERIVATIVE, REACTING PRODUCT WITH AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-12-09 | — | — | US | claimed |
| US-5644059-A | REACTION OF KETONE WITH ACRYLAMIDE AND AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-07-01 | — | — | US | claimed |
| EP-0488345-A1 | 1,4-Dihydropyridine derivatives and methods of producing the same | FUJIREBIO INC. (JP) | 1992-06-03 | — | — | EP | claimed |
| US-20030171345-A1 | 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives | SCHERING AG (DE) | 2003-09-11 | — | — | US | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5859244-A | EXHIBIT VASODILATING ACTIVITY BASED ON CALCIUM ANTAGONISM AND PLATELET-ACTIVATING FACTOR ANTAGONISM | FUJIREBIO, INC. (JP) | 1999-01-12 | — | — | US | disclosed |
| US-5763614-A | VASODILATION BASED ON CALCIUM ANTAGONISM AND PAF ANTAGONISM | FUJIREBIO INC. (JP) | 1998-06-09 | — | — | US | disclosed |
| US-5696268-A | REACTING N-ACYLAMINO ACID DERIVATIVE WITH OPTICALLY ACTIVE ENAMINE DERIVATIVE, REACTING PRODUCT WITH AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-12-09 | — | — | US | disclosed |
| US-5644059-A | REACTION OF KETONE WITH ACRYLAMIDE AND AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5367081-A | Vasodilator, antiallergen | FUJIREBIO INC. (JP) | 1994-11-22 | — | — | US | disclosed |
| EP-0488345-A1 | 1,4-Dihydropyridine derivatives and methods of producing the same | FUJIREBIO INC. (JP) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171345-A1 | 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives | CYP19A1, HSD17B11, GPER1 | CA12 2766/4885CA2 4543/4885CA9 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.